SRS Capital Advisors »

Galectin Therapeutics shares owned by SRS Capital Advisors

Quarter-by-quarter ownership of Galectin Therapeutics (GALT) shares owned by SRS Capital Advisors from 13F filings

Historical chart of SRS Capital Advisors investment in Galectin Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Galectin Therapeutics held by SRS Capital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Galectin Therapeutics by SRS Capital Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $220 52 4.23

More positions owned by SRS Capital Advisors

Vanguard Index Fds Growth Etf (VOO)
Ishares Tr Ishs 1-5yr Invs (OEF)
First Tr Exchange-traded Wtr Etf (FDL)
American Centy Etf Tr Us Large Cap Vlu (KORP)
Dimensional Etf Trust Intl Core Equity (DFAI)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Apple (AAPL)
Schwab Strategic Tr Us Tips Etf (SCHB)
Microsoft Corporation (MSFT)
First Tr Exchng Traded Fd Vi Smith Opport Fxd (FIXD)
First Tr Exchange Traded Risng Divd Achiv (FXN)
NVIDIA Corporation (NVDA)
First Tr Exch Traded Fd Iii Pfd Secs Inc Etf (FPE)
Spdr S&p 500 Etf Tr Tr Unit
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)

View all positions for SRS Capital Advisors

Top funds holding Galectin Therapeutics

Vanguard Group
Advisor Group Holdings
BlackRock
Geode Capital Management
Susquehanna International
Marshall Wace
Sontag Advisory
LPL Financial
Geneos Wealth Management
Commonwealth Equity Services
Vivaldi Capital Management
State Street Corporation
Morgan Stanley
Retirement Guys Formula
Sovran Advisors

View all funds holding Galectin Therapeutics